Fibrillar and oligomeric β-amyloid as distinct local biomarkers for Alzheimer's disease

Annals of the New York Academy of Sciences

Volumn 1097, Issue , 2007, Pages 239-258

  Montalto, Michael C ^a,c   Farrar, Gill ^b   Hehir, Cristina Tan ^a  

^a GE GLOBAL RESEARCH   (United States)

^b GE HEALTHCARE   (United Kingdom)

^c NONE   (United States)

Author keywords

Alzheimer's; Biomarkers; Imaging; Plaque; Soluble amyloid; amyloid imaging; amyloid oligomers

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; BENZOXAZOLE DERIVATIVE; BIOLOGICAL MARKER; CARBON 11; CONGO RED; FLUORODEOXYGLUCOSE; TRACER;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; CONFERENCE PAPER; DIAGNOSTIC IMAGING; DISEASE COURSE; HUMAN; MINI MENTAL STATE EXAMINATION; NEAR INFRARED SPECTROSCOPY; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PASSIVE IMMUNIZATION; POSITRON EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; BRAIN; BRAIN LEVEL; METABOLISM; PATHOLOGY; PHYSIOLOGY; REVIEW; SENILE PLAQUE; ULTRASTRUCTURE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BIOLOGICAL MARKERS; BLOOD-BRAIN BARRIER; BRAIN; BRAIN CHEMISTRY; HUMANS; SENILE PLAQUES;

EID: 34247611095     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1379.023     Document Type: Conference Paper

References (95)

1. GLENNER, G.G. & C.W. WONG. 1984. Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem. Biophys. Res. Commun 122: 1131-1135.
2. MASTERS, C.L. et al. 1985. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. USA 82: 4245-4249.
3. VASSAR, R. et al. 1999. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286: 735-741.
4. SINHA, S. et al. 1999. Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature 402: 537-540.
5. KHACHATURIAN, Z.S. & M.M. MESULUM, Eds. 2000. Alzheimer's disease: a compendium of current theories. Ann. N. Y. Acad. Sci. 924: 1-195.
6. BITAN, G., A. LOMAKIN & D.B. TEPLOW. 2001. Amyloid beta-protein oligomerization: prenucleation interactions revealed by photo-induced cross-linking of unmodified proteins. J. Biol. Chem. 276: 35176-35184.
7. URBANC, B. et al. 2004. In silico study of amyloid {beta}-protein folding and oligomerization. PNAS 101: 17345-17350.
8. INOUYE, H. & D.A. KIRSCHNER. 2000. A beta fibrillogenesis: kinetic parameters for fibril formation from Congo red binding. J. Struc. Biol. 130: 123-129.
9. GORMAN, P.M. et al. 2003. Alternate aggregation pathways of the Alzheimer β-amyloid peptide: Aβ association kinetics at endosomal pH. J. Mol. Biol. 325: 743-757.
10. IWATSUBO, T. et al. 1994. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 13: 45-53.
11. SHIBATA, M. et al. 2000. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest. 106: 1489-1499.
12. GHERSI-EGEA, J.F. et al. 1996. Fate of cerebrospinal fluid-borne amyloid beta-peptide: rapid clearance into blood and appreciable accumulation by cerebral arteries. J. Neurochem. 67: 880-883.
13. DEMATTOS, R.B. et al. 2002. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 295: 2264-2267.
14. PIKE, C.J. et al. 1991. In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res. 563: 311-314.
15. LORENZO, A. & B.A. YANKNER. 1994. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc. Natl. Acad. Sci. USA 91: 12243-12247.
16. DAHLGREN, K.N. et al. 2002. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J. Biol. Chem. 277: 32046-32053.
17. LI, Y.T., D.S. WOODRUFF-PAK & J.Q. TROJANOWSKI. 1994. Amyloid plaques in cerebellar cortex and the integrity of Purkinje cell dendrites. Neurobiol. Aging 15: 1-9.
18. KIRKITADZE, M.D., G. BITAN & D.B. TEPLOW. 2002. Paradigm shifts in Alzheimer's disease and other neurodegenerative disorders: the emerging role of oligomeric assemblies. J. Neurosci. Res. 69: 567-577.
19. NASLUND, J. et al. 2000. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 283: 1571-1577.
20. MCLEAN, C.A. et al. 1999. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46: 860-866.
21. LUE, L.F. et al. 1999. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol. 155: 853-862.
22. KLEIN, W.L. 2002. Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem. Int. 41: 345-352.
23. KUO, Y.M. et al. 1996. Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J. Biol. Chem. 271: 4077-4081.
24. WELLER, R.O. et al. 1998. Cerebral amyloid angiopathy: amyloid beta accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease. Am. J. Pathol. 153: 725-733.
25. BARGHORN, S. et al. 2005. Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease. J. Neurochem. 95: 834-847.
26. KAYED, R. et al. 2004. Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J. Biol. Chem. 279: 46363-46366.
27. GONG, Y. et al. 2003. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl. Acad. Sci. USA 100: 10417-10422.
28. LAMBERT, M.P. et al. 1998. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. USA 95: 6448-6453.
29. WALSH, D.M. et al. 2002. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416: 535-539.
30. DEMATTOS, R.B. et al. 2001. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 98: 8850-8855.
31. DODART, J.C. et al. 2002. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat. Neurosci. 5: 452-457.
32. WANG, J. et al. 1999. The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging. Exp. Neurol. 158: 328-337.
33. LESNE, S. et al. 2006.Aspecific amyloid-beta protein assembly in the brain impairs memory. Nature 440: 352-357.
34. KIM, H.J. et al. 2003. Selective neuronal degeneration induced by soluble oligomeric amyloid beta protein. FASEB J. 17: 118-120.
35. KAYED, R. et al. 2003. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300: 486-489.
36. KLYUBIN, I. et al. 2005. Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat. Med. 11: 556-561.
37. MOHS, R.C., W.G. ROSEN & K.L. DAVIS. 1983. The Alzheimer's disease assessment scale: an instrument for assessing treatment efficacy. Psychopharmacol. Bull. 19: 448-450.
38. FOLSTEIN, M.F., S.E. FOLSTEIN & P.R. MCHUGH. 1975. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12: 189-198.
39. MCKHANN, G. et al. 1984. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-944.
40. PETRELLA, J.R., R.E. COLEMAN & P.M. DORAISWAMY. 2003. Neuroimaging and early diagnosis of Alzheimer disease: a look to the future. Radiology 226: 315-336.
41. SILVERMAN, D.H. et al. 2001. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA 286: 2120-2127.
42. MOSCONI, L. et al. 2006. Visual rating of medial temporal lobe metabolism in mild cognitive impairment and Alzheimer's disease using FDG-PET. Eur. J. Nucl. Med. Mol. Imag. 33: 210-221.
43. MOTTER, R. et al. 1995. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann. Neurol. 38: 643-648.
44. HULSTAERT, F. et al. 1999. Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology 52: 1555-1562.
45. CSERNANSKY, J.G. et al. 2002. Relationships among cerebrospinal fluid biomarkers in dementia of the Alzheimer type. Alzheimer. Dis. Assoc. Disord. 16: 144-149.
46. MARUYAMA, M. et al. 2001. Cerebrospinal fluid amyloid beta(1-42) levels in the mild cognitive impairment stage of Alzheimer's disease. Exp. Neurol. 172: 433-436.
47. KUNG, M.P. et al. 2002. Radioiodinated styrylbenzene derivatives as potential SPECT imaging agents for amyloid plaque detection in Alzheimer's disease. J. Mol. Neurosci. 19: 7-10.
48. PODUSLO, J.F. et al. 1999. Receptor-mediated transport of human amyloid beta-protein 1-40 and 1-42 at the blood-brain barrier. Neurobiol. Dis. 6: 190-199.
49. PODUSLO, J.F. et al. 2002. Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging. Neurobiol. Dis. 11: 315-329.
50. KUNG, H.F. et al. 2003. Iodinated tracers for imaging amyloid plaques in the brain. Mol. Imag. Biol. 5: 418-426.
51. SHOGHI-JADID, K. et al. 2002. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer's disease. Am. J. Geriatr. Psychiatry 10: 24-35.
52. KLUNK, W.E. et al. 2004. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 55: 306-319.
53. VERHOEFF, N.P. et al. 2004. In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. Am. J. Geriatr. Psychiatry 12: 584-595.
54. NEWBERG, A.B. et al. 2006. Safety, biodistribution, and dosimetry of 123I-IMPY: a novel amyloid plaque-imaging agent for the diagnosis of Alzheimer's disease. J. Nucl. Med. 47: 748-754.
55. KLUNK, W.E., R.F. JACOB & R.P. MASON. 1999. Quantifying amyloid β-peptide (Aβ) aggregation using the Congo red-Aβ (CR-Aβ) spectrophotometric assay. Anal. Biochem. 266: 66-76.
56. MATHIS, C.A. et al. 2003. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J. Med. Chem. 46: 2740-2754.
57. FARRAR, G. 2005. Challenges in the development of novel PET agents. Turku PET Symposium. Abstract 49.
58. AGDEPPA, E.D. et al. 2001. Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease. J. Neurosci. 21: RC189.
59. VILLEMANGE, V. et al. 2006. 11C-PIB PET imaging in the different diagnosis of dementia. Society of Nuclear Medicine Annual Meeting. Abstact 209.
60. NEWBERG, A.B. et al. 2006. Use of 1231 IMPY SPECT to differentiate Alzheimer's disease from controls. Society of Nuclear Medicine Annual Meeting. Abstact 220.
61. BLOMQVIST, G. et al. 2006. Imaging amyloid depositions and glucose uptake changes in Alzheimer's disease: a follow-up study. Presented at the Annual Conference of the Academy of Molecular Imaging. Mol. Imag. Biol. 8: Abs no 88.
62. PETERSEN, R.C. 2003. Mild cognitive impairment clinical trials. Nat. Rev. Drug Discov. 2: 646-653.
63. KEPE, V. et al. 2006. Detection of MCI-AD and control -MCI conversions in Alzheimer's disease patients with (F-18) FDDNP PET. Society of Nuclear Medicine Annual Meeting. Abstact 208.
64. BENNETT, D.A. et al. 2006. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 66: 1837-1844.
65. MANI, R.B. 2004. The evaluation of disease modifying therapies in Alzheimer's disease: a regulatory viewpoint. Stat. Med. 23: 305-314.
66. BITAN, G. et al. 2003. Amyloid beta-protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways. Proc. Natl. Acad. Sci. USA 100: 330-335.
67. WALSH, D.M. et al. 2002. Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Biochem. Soc. Trans. 30: 552-557.
68. NICOLL, J.A. et al. 2003. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 9: 448-452.
69. PERMANNE, B. et al. 2002. Reduction of amyloid load and cerebral damage in a transgenic mouse model of Alzheimer's disease by treatment with a beta-sheet breaker peptide. FASEB J. 16: 860-862.
70. DE FELICE, F.G. & S.T. FERREIRA. 2002. Beta-amyloid production, aggregation, and clearance as targets for therapy in Alzheimer's disease. Cell. Mol. Neurobiol. 22: 545-563.
71. MAIORINI, A.F. et al. 2002. Potential novel targets for Alzheimer pharmacotherapy: I. Secretases. J. Clin. Pharm. Ther. 27: 169-183.
72. HOCK, C. et al. 2003. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38: 547-554.
73. WILCOCK, D.M. et al. 2004. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J. Neurosci. 24: 6144-6151.
74. CONWAY, K.A. et al. 2003. Emerging beta-amyloid therapies for the treatment of Alzheimer's disease. Curr. Pharm. Des. 9: 427-447.
75. SIMMONS, M.K. et al. 2005. A computational PET simulation model for imaging b-amyloid in mice. Mol. Imag. Biol. 7: 69-77.
76. URBANC, B. et al. 1999. Dynamics of plaque formation in Alzheimer's disease. Biophys. J. 76: 1330-1334.
77. CIRRITO, J.R. et al. 2003. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J. Neurosci. 23: 8844-8853.
78. WESTERMARK, G.T., K.H. JOHNSON & P. WESTERMARK. 1999. Staining methods for identification of amyloid in tissue. In Amyloid, Prions, and other Protein Aggregates, Methods in Enzymology, vol. 309. R., Wetzsl, Ed.: 3-25. Academic Press, San Diego, CA.
79. STILLER, D. & D. KATENKAMP. 1975. Histochemistry of amyloid. General considerations, light microscopical and ultrastructural examinations. Exp. Pathol. Suppl. 1: 1-116.
80. GLENNER, G.G. 1981. The bases of the staining of amyloid fibers: their physicochemical nature and the mechanism of their dye-substrate interaction. Prog. Histochem. Cytochem. 13: 1-37.
81. LEVINE, H., III. 1993. Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci. 2: 404-410.
82. KUNER, P. et al. 2000. Controlling polymerization of beta-amyloid and prion-derived peptides with synthetic small molecule ligands. J. Biol. Chem. 275: 1673-1678.
83. GEORGE, A.R. & D.R. HOWLETT. 1999. Computationally derived structural models of the beta-amyloid found in Alzheimer's disease plaques and the interaction with possible aggregation inhibitors. Biopolymers 50: 733-741.
84. MA, B. & R. NUSSINOV. 2002. Stabilities and conformations of Alzheimer's beta-amyloid peptide oligomers (Abeta 16-22, Abeta 16-35, and Abeta 10-35): Sequence effects. Proc. Natl. Acad. Sci. USA 99: 14126-14131.
85. AGDEPPA, E.D. et al. 2003. In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer's brain using the positron emission tomography molecular imaging probe 2-(1-[6-[(2-[(18)F] fluoroethyl)(methyl)amino]-2-naphthyl]ethylidene)malono nitrile. Neuroscience 117: 723-730.
86. ENGLER, H. et al. 2002. First human study with a benzothiazole amyloid-imaging agent in Alzheimer's disease and control subjects. Neurobiol. Aging 23: S429.
87. BACSKAI, B.J. et al. 2003. Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-{beta} ligand in transgenic mice. Proc. Natl. Acad. Sci. USA 100: 12462-12467.
88. OKAMURA, N. et al. 2004. Styrylbenzoxazole derivatives for in vivo imaging of amyloid plaques in the brain. J. Neurosci. 24: 2535-2541.
89. SUEMOTO, T. et al. 2004. In vivo labeling of amyloid with BF-108. Neurosci. Res. 48: 65-74.
90. ZHUANG, Z.P. et al. 2003. Structure-activity relationship of imidazo[1,2-a]pyridines as ligands for detecting beta-amyloid plaques in the brain. J. Med. Chem. 46: 237-243.
91. ZHEN, W. et al. 1999. Synthesis and amyloid binding properties of rhenium complexes: preliminary progress toward a reagent for SPECT imaging of Alzheimer's disease brain. J. Med. Chem. 42: 2805-2815.
92. SKOVRONSKY, D.M. et al. 2000. In vivo detection of amyloid plaques in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 97: 7609-7614.
93. HINTERSTEINER, M. et al. 2005. In vivo detection of amyloid-beta deposits by near-infrared imaging using an oxazine-derivative probe. Nat. Biotechnol. 23: 577-583.
94. WENGENACK, T.M., G.L. CURRAN & J.F. PODUSLO. 2000. Targeting Alzheimer amyloid plaques in vivo. Nat. Biotechnol. 18: 868-872.
95. JANKOWSKY, J.L. et al. 2005. Persistent amyloidosis following suppression of AB producyion in a transgenic model of Alzheimer's disease. PLoS Medicine 2: e355.